Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
83
Active, not recruiting, industry sponsors, Immunology and inflammation, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting139
- Completed1,148
83 trials
Showing 1 to 25, recently updated first.
- A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06975722 · 105 participants · Start Jul 7, 2025 · Primary completion Dec 17, 2026
Drug: SAR442970; Placebo · For: Ulcerative Colitis
Sites: Fairhope, Alabama; Escondido, California; Lancaster, California · 61 sites in all
- A Study of Obexelimab in Patients With Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
Zenas BioPharma (USA), LLCIndustry
NCT06559163 · 190 participants · Start Sep 17, 2024 · Primary completion Sep 23, 2026
Drug: Obexelimab; Placebo · For: Systemic Lupus Erythematosus
Sites: Peoria, Arizona; Fresno, California; Huntington Park, California · 110 sites in all
- A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT07175233 · 184 participants · Start Oct 28, 2025 · Primary completion Sep 23, 2026
Drug: SIM0278 injection · For: Atopic Dermatitis (AD)
Sites: Hangzhou, China; Shenyang, China
- A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseasePivotal-lookingActive, not recruiting
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT05668013 · 247 participants · Start Jan 11, 2023 · Primary completion Jan 5, 2026
Drug: TEV-48574 Dose Regimen A; TEV-48574 Dose Regiment B · For: Crohn Disease; Colitis, Ulcerative
Sites: San Diego, California; Kissimmee, Florida; Orlando, Florida · 93 sites in all
- Phase IIa Study Evaluating AZD7798 in Crohn's DiseasePivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06450197 · 120 participants · Start Aug 28, 2024 · Primary completion Apr 30, 2026
Drug: AZD7798 · For: Moderate to Severe Crohn's Disease
Sites: Phoenix, Arizona; Escondido, California; La Jolla, California · 116 sites in all
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisPivotal-lookingActive, not recruiting
Oruka Therapeutics, Inc.Industry
NCT07290569 · 160 participants (planned) · Start Dec 3, 2025 · Primary completion Oct 21, 2026
Drug: ORKA-001 · For: Plaque Psoriasis
Sites: Phoenix, Arizona; North Little Rock, Arkansas; Los Angeles, California · 36 sites in all
- A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisPivotal-lookingActive, not recruiting
Avalyn Pharma Inc.Industry
NCT06329401 · 398 participants · Start Apr 3, 2024 · Primary completion Jun 2027
Drug: AP01 · For: Pulmonary Fibrosis; Progressive Pulmonary Fibrosis; Pulmonary Fibrosis Secondary to Systemic Sclerosis and 7 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Los Angeles, California · 154 sites in all
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05242484 · 577 participants · Start Sep 19, 2022 · Primary completion May 15, 2025
Drug: Guselkumab; Golimumab and 2 more · For: Colitis, Ulcerative
Sites: Arcadia, California; Coronado, California; Lancaster, California · 403 sites in all
- A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06863961 · 162 participants · Start Apr 1, 2025 · Primary completion Jul 22, 2026
Drug: Afimkibart; Placebo · For: Atopic Dermatitis
Sites: Fountain Valley, California; Los Angeles, California; Tampa, Florida · 52 sites in all
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04033445 · 1,064 participants · Start Sep 26, 2019 · Primary completion Sep 19, 2023
Drug: Placebo; Guselkumab · For: Ulcerative Colitis
Sites: Lancaster, California; Los Angeles, California; Colorado Springs, Colorado · 392 sites in all
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05242471 · 703 participants · Start Jul 22, 2022 · Primary completion May 23, 2025
Drug: Guselkumab; Golimumab and 2 more · For: Crohn's Disease
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 456 sites in all
- A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07230860 · 189 participants · Start Jan 20, 2026 · Primary completion Nov 19, 2026
Drug: JNJ-95597528; Placebo · For: Dermatitis, Atopic
Sites: Fountain Valley, California; Los Angeles, California; Santa Ana, California · 62 sites in all
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03466411 · 1,409 participants · Start Apr 13, 2018 · Primary completion Oct 20, 2023
Drug: Guselkumab Dose 1; Guselkumab Dose 2 and 6 more · For: Crohn's Disease
Sites: Dothan, Alabama; Mobile, Alabama; Tucson, Arizona · 579 sites in all
- A Study Evaluating APG777 in Atopic DermatitisPivotal-lookingActive, not recruiting
Apogee Therapeutics, Inc.Industry
NCT06395948 · 470 participants · Start Apr 29, 2024 · Primary completion Nov 2026
Drug: APG777; Placebo · For: Atopic Dermatitis
Sites: Fountain Valley, California; Los Angeles, California; San Diego, California · 94 sites in all
- A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07321873 · 157 participants · Start Jan 15, 2026 · Primary completion Jun 28, 2027
Drug: JNJ-88545223; Placebo · For: Arthritis, Psoriatic
Sites: Searcy, Arkansas; Huntington Beach, California; San Diego, California · 75 sites in all
Ventus Therapeutics U.S., Inc.Industry
NCT07260877 · 24 participants (planned) · Start Dec 3, 2025 · Primary completion Dec 2026
Drug: VENT-03; Placebo · For: Cutaneous Lupus Erythematosus (CLE); Systemic Lupus Erythematosus; SLE and 2 more
Sites: Beverly Hills, California; Clearwater, Florida; DeBary, Florida · 34 sites in all
- Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06681324 · 24 participants · Start Dec 11, 2024 · Primary completion Aug 10, 2026
Drug: AZD7798 · For: Crohn's Disease
Sites: Leuven, Belgium; Padova, Italy; Roma, Italy · 17 sites in all
- A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic DermatitisActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07223697 · 120 participants (planned) · Start Jan 8, 2026 · Primary completion Mar 1, 2033
Drug: Afimkibart · For: Atopic Dermatitis
Sites: Los Angeles, California; Tampa, Florida; Alpharetta, Georgia · 31 sites in all
- A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusPivotal-lookingActive, not recruiting
BiogenBiogen (BIIB)
NCT05531565 · 450 participants (planned) · Start Sep 13, 2022 · Primary completion Oct 20, 2026
Drug: Litifilimab; Placebo · For: Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 315 sites in all
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT05995964 · 507 participants · Start Aug 22, 2023 · Primary completion Nov 12, 2026
Drug: PF-07275315; PF-07264660 · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Peoria, Arizona; Phoenix, Arizona · 96 sites in all
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruiting
Alpine Immune Sciences, Inc.Industry
NCT05732402 · 72 participants · Start Mar 15, 2023 · Primary completion Mar 2, 2028
Drug: Povetacicept · For: Lupus Nephritis; Immunoglobulin A Nephropathy; Membranous Nephropathy and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Valencia, California · 30 sites in all
- Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07486960 · 140 participants (planned) · Start Apr 20, 2026 · Primary completion Feb 17, 2027
Drug: Tulisokibart; Placebo · For: Psoriatic Arthritis
Sites: Sun City, Arizona; Tucson, Arizona; Riverside, California · 50 sites in all
- Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisPivotal-lookingActive, not recruiting
Oruka Therapeutics, Inc.Industry
NCT07474792 · 160 participants (planned) · Start Mar 19, 2026 · Primary completion Oct 2027
Drug: ORKA-002 · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Fountain Valley, California · 40 sites in all
- The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Pivotal-lookingActive, not recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT05540327 · 381 participants · Start Sep 16, 2022 · Primary completion Aug 12, 2028
Drug: M5049 low dose; M5049 medium dose and 2 more · For: Systemic Lupus Erythematosus
Sites: Torrance, California; Brandon, Florida; Miami, Florida · 122 sites in all
- Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseasePivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06293365 · 155 participants · Start Jul 2, 2024 · Primary completion Feb 17, 2026
Drug: VAY736 1ml PFS; VAY736 2 ml PFS and 1 more · For: Sjögrens Disease; Systemic Lupus Erythematosus; Rheumatoid Arthritis
Sites: Anniston, Alabama; Fullerton, California; La Palma, California · 37 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.